Krystal Biotech Inc is a biotechnology company focused on developing innovative gene therapies to treat debilitating skin and rare diseases. The company harnesses its proprietary, skin-targeted gene delivery platform to create treatments aimed at addressing the underlying genetic causes of these conditions. By advancing its pipeline of product candidates, Krystal Biotech seeks to provide transformative therapies that can improve the quality of life for patients affected by various skin disorders and other genetic conditions. The company's commitment to research and development ensures a strong focus on scientific excellence and innovative solutions in the field of gene therapy. Read More
The U.S. stock market is currently a landscape of contrasting forces, with robust bank earnings providing a bedrock of stability against the backdrop of persistent trade tensions with China and intermittent volatility. In this nuanced environment, a compelling narrative is emerging around growth stocks exhibiting significant insider ownership. This
Krystal Biotech (NASDAQ: KRYS) has outperformed the market over the past 5 years by 16.54% on an annualized basis producing an average annual return of 31.18%. Currently, Krystal Biotech has a market capitalization of $4.73 billion.
The FDA approved Krystal Biotech's Vyjuvek label update, expanding treatment to newborns and offering flexible wound care based on real-world patient data.
